A cRGD-modified cationic liposome and nucleic acid complex thereof and application in anti-tumor

By modifying cRGD cyclic peptides on the surface of cationic liposomes, combining integrin receptors on tumor cells and neovascular endothelial cells, a targeted delivery system was developed, solving the problem that the in vivo trafficking of liposomes in the prior art is not selective. and tumor heterogeneity lead to inefficient treatment, achieving efficient delivery of OC2 shRNA and inhibiting the growth of breast cancer cells.

CN115702882BActive Publication Date: 2024-11-12JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110899815.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-08-06
Publication Date
2024-11-12
Estimated Expiration
2041-08-06

AI Technical Summary

Technical Problem

The existing liposome transport in vivo is not selective, resulting in low accumulation efficiency in tumor sites, and tumor heterogeneity makes the EPR effect not universally applicable to all cancer patients, making it difficult to achieve effective targeted treatment.

Method used

The development of targeted delivery systems is achieved by modifying cRGD cyclic peptides on the surface of cationic liposomes, combining integrin receptors on tumor cells and neovascular endothelial cells, including the use of cationic lipids such as DOTMA, DC-Chol and DDAB , neutral assisted lipids such as cholesterol and DOPE, polyethylene glycol derivatives such as PEG2000, and cRGD modified cationic liposomes were prepared by freeze-drying, binding to OC2 shRNA plasmids to target the silencing of the OC2 gene.

Benefits of technology

It significantly enhances the targeting and transfection efficiency of liposomes on tumor cells, achieves efficient delivery of OC2 shRNA to tumor sites, inhibits the proliferation of breast cancer cells and triggers apoptosis, and has the potential to serve as a delivery vector for breast cancer gene therapy. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115702882B_ABST
    Figure CN115702882B_ABST
Patent Text Reader

Abstract

The present invention discloses a cRGD-modified cationic liposome and a nucleic acid complex thereof and an application in anti-tumor. The cRGD-modified cationic liposome comprises a cationic lipid, a neutral auxiliary lipid, a derivative of polyethylene glycol and a cRGD-modified PEGylated lipid, and is a cRGD-modified nucleic acid nano-delivery system that can specifically recognize integrin receptors on tumor cells and neovascular endothelial cells and has tumor targeting. The cRGD-modified cationic liposome in the present invention can effectively encapsulate nucleic acid drugs such as OC2shRNA expression plasmids to form a stable liposome nucleic acid complex, which can significantly enhance the targeting and transfection efficiency of liposomes to tumor cells, and can be used for gene therapy of solid tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gene therapy drugs, and in particular to a cRGD-modified cationic liposome and a nucleic acid complex thereof, and applications thereof in anti-tumor aspects. Background Art

[0002] In 2020, breast cancer became the most common cancer in the world with the highest incidence, and it is also the second leading cause of death among women. Breast cancer is highly heterogeneous, and the choice and efficacy of its treatment are highly dependent on the molecular typing of breast cancer. Clinically, the treatment of breast cancer is mainly drug therapy (chemotherapy and endocrine therapy), but drug therapy inevitably leads to drug resistance, which usually leads to disease recurrence, tumor metastasis and worsening of malignancy. Therefore, new treatment methods, such as gene therapy, are urgently needed for the clinical treatment of breast cancer. The discovery of breast cancer susceptibility genes or biomarkers may provide new gene therapy targets for breast cancer.

[0003] One cut domain family member 2 (ONECUT 2), also known as OC2, is a newly discovered member of the ONECUT transcription factor family that regulates the expression of target genes by binding to specific DNA sequences. From the discovery of OC2 in 1999 to 2020, abnormal expression of OC2 has gradually been shown to be involved in the development of various cancers. Abnormal expression of OC2 is present in malignant tumors such as prostate cancer, gastric cancer, colon cancer, renal clear cell carcinoma, brain cancer, and lung cancer and is significantly associated with poor clinical outcomes, suggesting that it may play a broader role in invasive cancers, but further research is needed to fully understand the role of OC2 in tumor heterogeneity and tumor evolution. As a transcription factor, OC2 widely regulates the expression of proteins related to cell proliferation, migration, adhesion, differentiation, and cellular material metabolism, but its role in breast cancer is not clear enough, and further research is needed to clarify whether OC2 can be used as a new target for breast cancer treatment.

[0004] RNA interference (RNAi) is a sequence-specific post-transcriptional gene silencing mechanism mediated by double-stranded RNA and is one of the important means of gene therapy. Compared with chemotherapy, RNAi-based therapy has the advantages of precise functional mechanism, great potential, and high specificity of gene silencing mechanism. The use of RNAi in cancer treatment can target multiple genes involved in various cellular pathways of tumor progression and develop personalized drugs for specific patients. However, gene therapy is a typical technology-driven industry, and its clinical transformation is highly limited by the research and development of delivery systems.

[0005] Liposomes are one of the most widely used non-viral vectors in clinical practice and have been proven to be a safe and effective delivery system. However, liposomes without any modifications are not selective in their transport in vivo. They are generally accumulated in the tumor site through the enhanced and penetration effect (EPR) of the tumor, even if only less than 1% of the drug is accumulated in the tumor. However, due to tumor heterogeneity, the EPR effect is not universally applicable to all cancer patients. Therefore, in order to enhance the distribution of liposomes in tumors, targeted liposome technology has been widely used to modify the carriers of anticancer drugs. By adding specific ligand modifications to the surface of liposomes, their ability to target specific cells can be achieved. Breast cancer cells and endothelial cells of tumor angiogenesis highly express integrins, which specifically recognize the arginine-glycine-aspartic acid (Arg-Gly-Asp, RGD) tripeptide sequence, while cRGD is a c(RGDfK) cyclic peptide, which has a stronger ability to penetrate cells. Summary of the invention

[0006] The first object of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a cRGD-modified cationic liposome.

[0007] The second object of the present invention is to provide a method for preparing the cRGD-modified cationic liposome.

[0008] The third object of the present invention is to provide the use of the cRGD-modified cationic liposome in preparing a drug carrier.

[0009] The fourth object of the present invention is to provide a cRGD-modified cationic liposome nucleic acid drug preparation.

[0010] The fifth object of the present invention is to provide a method for preparing the cRGD-modified cationic liposome nucleic acid drug preparation.

[0011] The purpose of the present invention is achieved through the following technical solutions:

[0012] A cRGD-modified cationic liposome comprises a cationic lipid, a neutral auxiliary lipid, a polyethylene glycol derivative and a cRGD-modified PEGylated lipid.

[0013] The cationic lipid is at least one of dioleoyl trimethylammonium chloride (DOTMA), (2,3-dioleoyl-propyl)-trimethylamine (DOTAP), carbamoyl cholesterol (DC-Chol) and didodecyl dimethyl ammonium bromide (DDAB); preferably (2,3-dioleoyl-propyl)-trimethylamine.

[0014] The neutral auxiliary lipid is at least one of cholesterol (Chol), dioleoylphosphatidylethanolamine (DOPE) and dioleoylphosphatidylcholine (DOPC); preferably cholesterol.

[0015] The molecular weight of the polyethylene glycol (PEG) is 500-3000, preferably 2000.

[0016] The polyethylene glycol derivative is preferably 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG2000).

[0017] The cRGD-modified PEGylated lipid is distearoylphosphatidylethanolamine-polyethylene glycol 2000-cyclic peptide (DSPE-PEG2000-cRGD).

[0018] The molar ratio of the cationic lipid, the neutral auxiliary lipid, the polyethylene glycol derivative and the cRGD-modified PEGylated lipid is 50:42:1.8-2:6, preferably 50:42:2:6.

[0019] The cRGD-modified cationic liposomes are vesicles with a phospholipid bilayer, which are mainly made of cationic lipids and neutral auxiliary lipids. Polyethylene glycol derivatives and cRGD ligands are introduced for PEGylation and cRGD modification, respectively, to achieve long circulation and tumor targeting in vivo.

[0020] The preparation method of the cRGD-modified cationic liposomes can be a thin film dispersion method, a reverse evaporation method, an ethanol injection method, and a freeze drying method; preferably, the freeze drying method or the ethanol injection method; more preferably, the preparation method is prepared by dissolving in an organic solvent and adopting a freeze drying method; specifically, the steps are as follows:

[0021] (1) adding cationic lipids, neutral auxiliary lipids, polyethylene glycol derivatives and cRGD-modified PEGylated lipids into an organic solvent, and mixing them thoroughly under water bath ultrasound to obtain a liposome oil phase solution;

[0022] (2) adding sucrose solution to the liposome oil phase solution obtained in step (1), mixing evenly, and obtaining a liposome suspension;

[0023] (3) freeze-drying the liposome suspension obtained in step (2) to obtain liposome freeze-dried powder;

[0024] (4) adding water to the lyophilized liposome powder obtained in step (3) and mixing evenly to hydrate the liposomes, and then extruding the hydrated liposomes using a liposome extruder to obtain cRGD-modified cationic liposomes.

[0025] The molar ratio of the cationic lipid, the neutral auxiliary lipid, the polyethylene glycol derivative and the cRGD-modified PEGylated lipid described in step (1) is 50:42:1.8-2:6, preferably 50:42:2:6.

[0026] The organic solvent described in step (1) is at least one of chloroform, methanol and tert-butanol; preferably tert-butanol, or a mixture of chloroform and methanol; more preferably tert-butanol.

[0027] The concentrations of the cationic lipids, neutral auxiliary lipids, polyethylene glycol derivatives and cRGD-modified PEGylated lipids in the liposome oil phase solution described in step (1) are all 1-5 mg / mL, preferably 1 mg / mL.

[0028] The concentration of the sucrose solution described in step (2) is preferably 15 mg / mL.

[0029] The amount of sucrose added in step (2) is calculated based on 7.5% of its mass percentage in the system.

[0030] The uniform mixing in step (2) is achieved by vortex oscillation; preferably, the vortex oscillation is performed for 20 seconds to achieve uniform mixing.

[0031] The pre-freezing conditions described in step (3) are: first pre-freezing at an ultra-low temperature of -80°C for 12 hours, and then freeze-drying at -80°C and less than 0.07 mbar for 72 hours.

[0032] The water described in step (4) is preferably sterile ultrapure water.

[0033] The amount of water (hydration volume) described in step (4) is added according to actual needs, and is generally less than the volume of the original liposome suspension before lyophilization. In the lyophilization bottle used for lyophilization, the volume of the liposome suspension before lyophilization is generally less than or equal to 1 / 5 of the volume of the lyophilization bottle. Specifically, taking a 10mL lyophilization bottle as an example, when the volume of the liposome suspension in the lyophilization bottle is less than or equal to 2mL, after lyophilization, the hydration volume when water is added for hydration is about 150 to 500μL (preferably 300μL).

[0034] The liposome extruder described in step (4) is preferably a liposome extruder LE-1.

[0035] The extrusion conditions in step (4) are: extruding through a 400 nm and a 200 nm polycarbonate film in sequence; preferably, extruding through a 400 nm and a 200 nm polycarbonate film in sequence for more than 11 times.

[0036] The cRGD-modified cationic liposome is used in the preparation of drug carriers and / or anti-tumor drugs.

[0037] The drug carrier is a gene therapy delivery vector; preferably a delivery vector for breast cancer gene therapy.

[0038] The drug in the drug carrier and anti-tumor drug is a nucleic acid drug; more preferably, it is a shRNA drug; and even more preferably, it is an OC2 shRNA plasmid. The shRNA provided by the present invention is an shRNA plasmid that targets and silences breast cancer cells OC2, and is delivered to tumor cells through the liposomes provided by the present invention. After silencing OC2 in the cell, the purpose of inhibiting breast cancer cell proliferation and inducing tumor cell apoptosis is achieved.

[0039] The tumor is preferably breast cancer, ovarian cancer, brain cancer or prostate cancer with high integrin expression; more preferably breast cancer.

[0040] A cRGD-modified cationic liposome nucleic acid complex (i.e. nucleic acid drug preparation) contains the above-mentioned cRGD-modified cationic liposome and nucleic acid drugs.

[0041] The nucleic acid drug is shRNA; preferably, it is shRNA (OC2shRNA plasmid) that can target and silence OC2 gene expression.

[0042] The shRNA sequence in the OC2 shRNA plasmid is as follows:

[0043] Sense:5'-GCCAGCTGGAAGAAATCAACA-3';

[0044] anti-sense:5'-TGTTGATTTCTTCCAGCTGGC-3'.

[0045] The nitrogen-phosphorus ratio (N / P) of the nucleic acid drug and the cRGD-modified cationic liposome is 1:2-4, preferably 1:4.

[0046] The cRGD-modified cationic liposome nucleic acid complex may further contain a lyophilization protectant.

[0047] The freeze-drying protective agent is sucrose.

[0048] The added amount of the sucrose is calculated based on 7.5% of its mass percentage in the system.

[0049] The preparation method of the cRGD-modified cationic liposome nucleic acid complex comprises the following steps: uniformly mixing the cRGD-modified cationic liposome and nucleic acid drugs, and incubating at room temperature to obtain the cRGD-modified cationic liposome nucleic acid complex.

[0050] The room temperature incubation time is preferably about 25 minutes.

[0051] The application of the cRGD-modified cationic liposome nucleic acid complex in the preparation of anti-tumor drugs.

[0052] The tumor is preferably breast cancer, ovarian cancer, brain cancer, or prostate cancer that highly expresses integrin; more preferably, breast cancer.

[0053] Compared with the prior art, the present invention has the following advantages and effects:

[0054] (1) The present invention provides a cationic liposome targeting integrin receptors. The cationic liposome is a nucleic acid nano-delivery system modified with cRGD, which can specifically recognize integrin receptors on tumor cells and neovascular endothelial cells. The cRGD ligand interacts with the integrin receptor through specific ligand-receptor interaction, thereby enhancing the liposome's recognition ability and specific interaction with tumor cells, and has tumor targeting properties.

[0055] (2) The cationic liposomes in the present invention are prepared by a simple freeze-drying and rehydration method, which is easy to scale up and produce on a large scale in industrial production, and the prepared cationic liposomes are easy to store and transport.

[0056] (3) The cationic liposomes modified with the ligand cRGD in the present invention specifically target tumor cells and tumor neovascular endothelial cells to package the OC2 shRNA expression plasmid to achieve the purpose of targeting breast cancer cells and inducing apoptosis of breast cancer cells. That is, the cationic liposomes can effectively encapsulate the OC2 shRNA expression plasmid, can efficiently mediate gene transfection and inhibit tumor growth in vivo and in vitro, and have the potential to be used as a delivery vector for breast cancer gene therapy.

[0057] (4) Although long-circulating liposomes can reduce the nonspecific adsorption of plasma proteins to liposomes to a certain extent, their ability to enter cells is also greatly weakened. The present invention significantly enhances the targeting and transfection efficiency of liposomes to tumor cells by introducing cRGD into the liposome formula. In vivo, it can deliver the encapsulated gene drug OC2 shRNA to the tumor site and exert an anti-tumor effect.

[0058] (5) The liposome preparation method provided by the present invention has a simple process, and the freeze-drying method protects the activity of the targeting polypeptide cRGD. The prepared freeze-dried product has good stability and a long storage time, and is suitable for industrial mass production.

[0059] (6) The present invention also provides a method for preparing a liposome nucleic acid drug preparation. The cationic liposomes are incubated with nucleic acids at room temperature to form a stable liposome nucleic acid complex, which has the ability to target tumors and can be used for gene therapy of solid tumors, such as for targeted therapy of breast cancer, ovarian cancer, brain cancer, and prostate cancer that highly express integrins. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 This is a transmission electron microscopy image of cRGD-CL.

[0061] Figure 2 is the hydrodynamic particle size distribution diagram of cRGD-CL.

[0062] Figure 3 This is a graph showing the results of a 1% agarose gel blocking experiment of cRGD-CL / OC2 shRNA at N / P values ​​of 0.5, 1, 2, 3, and 4.

[0063] Figure 4 It is the FITC fluorescence intensity graph after MCF-7 cells were incubated with FITC-labeled CL and cRGD-CL for 1, 2 and 4 h.

[0064] Figure 5 This is the fluorescence image of MCF-7 cells transfected with cRGD-CL and CL for 48 hours.

[0065] Figure 6 These are images of tumors in each group of mice collected 20 days after treatment.

[0066] Figure 7 These are the in vivo images 3, 5 and 8 hours after tail vein injection of cRGD-CL into the subcutaneous tumor transplanted nude mouse model. DETAILED DESCRIPTION

[0067] The present invention will be described in further detail below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The test methods for which specific experimental conditions are not specified in the following examples are usually carried out according to conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, the reagents and raw materials used in the present invention can be obtained commercially.

[0068] The cationic lipid DOTAP (chemical name: (2,3-dioleoyl-propyl)-trimethylammonium-chloride, also known as: (2,3-dioleoyl-propyl)-trimethylamine; CAS No. 132172-61-3), the polyethylene glycol derivative PEG2000-DMG (chemical name: 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000, CAS: 160743-62-4) and the cRGD-modified PEGylated lipid DSPE-PEG2000-cRGD (distearyl phosphatidylethanolamine-polyethylene glycol 2000-cyclic peptide, CAS: #R-9995, Ruixibio) involved in the embodiments of the present invention can be obtained through conventional commercial sources.

[0069] The OC2 shRNA plasmid involved in the embodiment of the present invention is obtained by first designing OC2-specific shRNA and then entrusting Jima Gene Co., Ltd. to synthesize it; wherein,

[0070] The OC2-specific shRNA sequence is as follows:

[0071] Sense:5'-GCCAGCTGGAAGAAATCAACA-3';

[0072] anti-sense:5'-TGTTGATTTCTTCCAGCTGGC-3'.

[0073] Example 1 Preparation of cationic liposomes (CL) and cRGD-modified cationic liposomes (cRGD-CL)

[0074] (1) Take out DOTAP, cholesterol, PEG2000-DMG and DSPE-PEG2000-cRGD from the -20℃ refrigerator, weigh each component and dissolve it in tert-butyl alcohol (use ultrasonic cleaning machine water bath ultrasonic for about 20 minutes at room temperature until the solute is fully dissolved) to form the oil phase stock solution of each lipid (1 mg / mL). To ensure the sterility and dust-free preparation environment, the following operations should be carried out in a clean bench.

[0075] (2) Use a pipette to pipette 344 μL of DOTAP stock solution, 162 μL of cholesterol stock solution, 49 μL of PEG2000-DMG stock solution and 197 μL of DSPE-PEG2000-cRGD stock solution into the same 5 mL centrifuge tube (DOTAP: cholesterol: PEG2000-DMG: DSPE-PEG2000-cRGD = 50:42:2:6, molar ratio) to form an oil phase solution of cRGD-CL, and 344 μL of DOTAP stock solution, 162 μL of cholesterol stock solution, and 198 μL of PEG2000-DMG stock solution (DOTAP: cholesterol: PEG2000-DMG = 50:42:8, molar ratio) into the same 5 mL centrifuge tube to form an oil phase solution of CL.

[0076] (3) Add an equal volume of a sterile aqueous solution containing 15% (mass fraction) sucrose to the liposome oil phase solution prepared in step (2), and immediately vortex for 20 seconds to form a liposome suspension.

[0077] (4) The liposome suspension was transferred to a 10 mL freeze-drying bottle, covered with a rubber stopper, and quickly pre-frozen in a -80°C ultra-low temperature refrigerator for 12 h. It was then quickly transferred to a -80°C freeze dryer partition and sublimated for 72 h at less than 0.07 mbar to obtain a liposome freeze-dried powder.

[0078] (5) Sterile dust-free ultrapure water (300 uL) was added to the lyophilized liposome powder, and the mixture was immediately shaken. The hydrated liposomes were extruded 11 times through 400 nm and 200 nm polycarbonate membranes using a liposome extruder LE-1 to obtain cRGD-modified cationic liposomes (cRGD-CL) and cationic liposomes (CL). The liposomes were sealed and stored in the dark at 4 °C.

[0079] Transmission electron microscopy showed that cRGD-CL was a spherical unilamellar liposome with uniform particle size distribution ( Figure 1 ), the particle size of cRGD-CL was 125 nm as measured by dynamic light scattering, and the particle size distribution was narrow ( Figure 2 ).

[0080] Example 2 Preparation of dye-labeled cRGD-CL and CL

[0081] (1) Take out DOTAP, cholesterol, PEG2000-DMG and DSPE-PEG2000-cRGD from the -20℃ refrigerator, weigh each component and dissolve it in tert-butyl alcohol (use ultrasonic cleaning machine water bath ultrasonic for about 20 minutes at room temperature until the solute is fully dissolved) to form the oil phase stock solution of each lipid (1 mg / mL). To ensure the sterility and dust-free preparation environment, the following operations should be carried out in a clean bench.

[0082] (2) Use a pipette to pipette 344 μL of DOTAP stock solution, 162 μL of cholesterol stock solution, 44.5 μL of PEG2000-DMG stock solution and 197 μL of DSPE-PEG2000-cRGD stock solution into the same 5 mL centrifuge tube (DOTAP: cholesterol: PEG2000-DMG: DSPE-PEG2000-cRGD = 50:42:1.8:6, molar ratio) to form an oil phase solution of cRGD-CL, and 344 μL of DOTAP stock solution, 162 μL of cholesterol stock solution, and 193 μL of PEG2000-DMG stock solution (DOTAP: cholesterol: PEG2000-DMG = 50:42:7.8, molar ratio) into the same 5 mL centrifuge tube to form an oil phase solution of CL. An equal volume of a sterile aqueous solution containing 15% (mass fraction) sucrose was added to the prepared liposome oil phase solution, and the mixture was immediately vortexed for 20 seconds to form a liposome suspension.

[0083] (3) Transfer the liposome suspension to a 10 mL brown lyophilization bottle, add 0.002 μmol FITC-DHPE (CAS: Catalog Number: #F362, Invitrogen) or 0.002 μmol DiR lodide (CAS: Catalog Number: #CD4672, Coolaber) in a dark place, and immediately shake to form FITC- or DiR-labeled liposomes.

[0084] (4) After being rapidly pre-frozen in a -80°C ultra-low temperature freezer for 12 h, the samples were quickly transferred to a -80°C freeze dryer and subjected to sublimation drying at less than 0.07 mbar for 72 h to obtain cRGD-CL and CL freeze-dried powders.

[0085] (5) Sterile dust-free ultrapure water (300 uL) was added to the lyophilized powders of cRGD-CL and CL, respectively, and the mixture was immediately shaken. The hydrated liposomes were extruded 11 times through 400 nm and 200 nm polycarbonate membranes using a liposome extruder LE-1 to obtain dye-labeled cRGD-CL and CL (FITC-CL, FITC-cRGD-CL, DiR-CL, DiR-cRGD-CL), which were then sealed and stored at 4 °C in the dark.

[0086] Example 3 Determination of the encapsulation ability of cRGD-CL for OC2 shRNA plasmid

[0087] Encapsulation efficiency is one of the important indicators for evaluating liposomes as gene delivery vectors. In this example, cRGD-CL / OC2 shRNA complexes were first prepared, and the cRGD-CL prepared in Example 1 was divided into 5 portions, each of 60 μL, and 64, 32, 16, 10.7, and 8 μg of OC2 shRNA plasmid were added respectively, mixed, and incubated at room temperature for 25 minutes to obtain liposome nucleic acid complexes with N / P ratios (nitrogen-phosphorus ratio) of 0.5, 1, 2, 3, and 4. cRGD-CL / OC2 shRNA at different N / P ratios was directly added to 1% agarose gel, and the electrophoresis conditions were: 110V, 45min, and after the electrophoresis was completed, it was photographed under a gel imager.

[0088] The results are as follows Figure 3 As shown: when the N / P ratio is >2, cRGD-CL can completely block the migration of DNA in the gel, indicating that cRGD-CL can form a stable complex with DNA.

[0089] Example 4 In vitro targeting evaluation of cRGD-CL loaded with OC2 shRNA

[0090] One day before the experiment, MCF-7 cells (Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences) were seeded in 12-well plates at 8 × 10 4 Cells were cultured overnight until they adhered to the wall. The old culture medium was discarded, the cells were washed twice with PBS buffer, 1 mL of Opti-MEM culture medium was added, and FITC-labeled CL (FITC-CL) and cRGD-CL (FITC-cRGD-CL) (18 μL each) prepared in Example 2 were added to each well, and incubated for 1, 2 and 4 h, respectively. After the incubation, the cells were washed 3 times with PBS buffer for 5 min each time to remove free FITC-CL or FITC-cRGD-CL. The cells were digested with 0.25% trypsin, collected by centrifugation, and finally resuspended with 100 μL of PBS buffer. The FITC fluorescence intensity was detected by flow cytometry. After the experiment, the corresponding fluorescence intensity was quantified using Flow Jo 7.6.1 software (three parallel wells).

[0091] The results are as follows Figure 4 As shown: Compared with CL, cRGD modification significantly enhanced the binding ability of liposomes to tumor cells.

[0092] Example 5 Determination of transfection efficiency of cRGD-CL loaded with OC2 shRNA

[0093] One day before the experiment, MCF-7 cells were cultured at 8×10 4The cells were inoculated at a density of 100 μL / well in a 12-well plate and cultured overnight in a 37°C humidified incubator (5% CO2). When the cells grew to 70-80% confluence, the old culture medium was discarded, and after washing twice with PBS buffer, 800 μL Opti-MEM culture medium was added and placed in an incubator for transfection. 18 μL of cRGD-CL or CL prepared in Example 1 and 1.5 μg OC2 shRNA plasmid were diluted with 100 μL Opti-MEM culture medium in two EP tubes, respectively, and the plasmid dilution was added to the liposome dilution, carefully pipetted to mix, and incubated at room temperature for 25 minutes to obtain liposome / OC2 shRNA plasmid complexes (CL / OC2 shRNA, cRGD-CL / OC2 shRNA). Take out the cell plate to be transfected from the 37°C incubator, add the liposome / OC2 shRNA plasmid complex prepared above dropwise and evenly to each well (200 μL liposome / OC2 shRNA plasmid complex prepared above), and shake horizontally to mix. Place in a 37°C, 5% incubator for 48 hours. After digestion and centrifugation to collect the cells, resuspend the cells with 100 μL PBS, use flow cytometry to detect the GFP expression level of the cells (OC2 shRNA plasmid contains GFP expression tag), and use Flow Jo 7.6.1 software to quantify the corresponding fluorescence intensity (three parallels per well).

[0094] The results are as follows Figure 5 As shown: Compared with CL without added targeting modification, the introduction of cRGD modification in liposomes significantly enhanced its transfection efficiency in tumor cells.

[0095] Example 6 Evaluation of the anti-tumor effect of cRGD-CL loaded with OC2 shRNA in vivo

[0096] First, a nude mouse model of MCF-7 subcutaneous transplanted tumor (BALB / C nude mouse) was constructed (SPF BALB / c-nu, 4 weeks old, 18 g, female, purchased from Beijing Huafukang Biotechnology Co., Ltd.). MCF-7 cells in good growth state and in the logarithmic growth phase were digested with trypsin and resuspended in an appropriate amount of physiological saline at 3.0×10 6 The cells were inoculated into the right lower armpit of BALB / C nude mice at a density of 100 μL / cell and the tumor size was observed every day. 3The tumor-bearing nude mice were randomly divided into 2 groups, 5 mice in each group, and the PBS buffer or cRGD-CL / OC2 shRNA complex (prepared in Example 5) was injected into the tail vein. The injection amount of cRGD-CL / OC2 shRNA complex represented by OC2 shRNA and liposome was 2 mg / kg and 35 mg / kg, respectively. According to the tumor growth, the drug was administered once every 2 days or 1 day, the treatment period was 20 days, and a total of 9 doses were administered. On the 20th day, the mice were euthanized, the tumors were removed, and photos were taken.

[0097] The results are as follows Figure 6 As shown: Compared with the PBS group, the tumor growth of the cRGD-CL / OC2 shRNA group was significantly inhibited after 20 days of treatment.

[0098] Example 7 Evaluation of tumor targeting of cRGD-CL in vivo

[0099] Construction of MCF-7 subcutaneous transplanted tumor nude mouse model: MCF-7 cells in good growth state and in logarithmic growth phase were digested with trypsin, resuspended in appropriate amount of physiological saline, and concentrated to 3.0×10 6 The cells were inoculated into the right lower armpit of BALB / C nude mice (SPF BALB / c-nu, 4 weeks old, 18 g, female, purchased from Beijing Huafukang Biotechnology Co., Ltd.) at a density of 100 μL / cell and the tumor size was observed every day. When the tumor volume grew to 200 mm 3 Around 1:10 pm, the tail vein was injected with 100 μL of DiR-cRGD-CL prepared in Example 2. At time intervals of 3, 5 and 8 h after the injection, the mice were anesthetized by intraperitoneal injection of Avertin, and fluorescent imaging of the mice was performed using a small animal in vivo imaging system (IVIS Lumina Series III).

[0100] The results are as follows Figure 7 As shown: cRGD-CL can reach the tumor site in 5 hours.

[0101] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention. Sequence Listing <110> Jinan University <120> A cRGD-modified cationic liposome and nucleic acid complex thereof and application in anti-tumor <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> Sense <400> 1 gccagctgga agaaatcaac a 21 <210> 2 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> anti-sense <400> 2 tgttgatttc ttccagctgg c 21

Claims

1. A use of a cRGD-modified cationic liposome nucleic acid complex in the preparation of an anti-breast cancer drug, characterized in that: The cRGD-modified cationic liposome nucleic acid complex contains cRGD-modified cationic liposome and nucleic acid drugs; The cRGD-modified cationic liposomes are prepared by the following method: (1) adding cationic lipids, neutral auxiliary lipids, polyethylene glycol derivatives and cRGD-modified PEGylated lipids into an organic solvent, and mixing them thoroughly under water bath ultrasound to obtain a liposome oil phase solution; (2) adding sucrose solution to the liposome oil phase solution obtained in step (1), mixing evenly, and obtaining a liposome suspension; (3) freeze-drying the liposome suspension obtained in step (2) to obtain liposome freeze-dried powder; (4) adding water to the lyophilized liposome powder obtained in step (3) and mixing them evenly to hydrate the liposomes, and then extruding the hydrated liposomes using a liposome extruder to obtain cRGD-modified cationic liposomes; The cationic lipid described in step (1) is (2,3-dioleoyl-propyl)-trimethylamine; The neutral auxiliary lipid described in step (1) is cholesterol; The polyethylene glycol derivative described in step (1) is 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000; The cRGD-modified PEGylated lipid described in step (1) is distearoylphosphatidylethanolamine-polyethylene glycol 2000-cyclopeptide; The molar ratio of the cationic lipid, the neutral auxiliary lipid, the polyethylene glycol derivative and the cRGD-modified PEGylated lipid described in step (1) is 50:42:1.8-2:6; The amount of sucrose added in step (2) is calculated based on its concentration in the system being 7.5% by mass; The nucleic acid drug is an OC2 shRNA plasmid; The shRNA sequence in the OC2 shRNA plasmid is as follows: Sense: 5'-GCCAGCTGGAAGAAATCAACA -3'; anti-sense: 5'-TGTTGATTTCTTCCAGCTGGC-3'; The nitrogen-phosphorus ratio of the nucleic acid drug and the cRGD-modified cationic liposome is 1:2-4.

2. The use according to claim 1, characterized in that: The organic solvent in step (1) is at least one of chloroform, methanol and tert-butyl alcohol; The concentration of the sucrose solution in step (2) is 15 mg / mL; The uniform mixing in step (2) is uniform mixing by vortex oscillation; The freeze-drying conditions in step (3) are: pre-freezing at -80°C for 12 h, and then freeze-drying at -80°C and less than 0.07 mbar for 72 h; The water described in step (4) is sterile ultrapure water; The extrusion conditions described in step (4) are: extruding through 400 nm and 200 nm polycarbonate films in sequence.

3. The use according to claim 1, characterized in that: It also contains a lyoprotectant; The freeze-drying protective agent is sucrose; The amount of sucrose added is calculated based on its concentration in the system being 7.5% by mass.